The question regarding an Apixaban shortage in the UK in 2026 is not supported by publicly available information at this time. Drug shortages are typically dynamic and can be influenced by various factors, including manufacturing issues, supply chain disruptions, or increased demand.
What is Apixaban used for?
Apixaban is an anticoagulant medication, commonly known by the brand name Eliquis. It is used to prevent blood clots in several conditions, including stroke in people with non-valvular atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE). It is also used to prevent DVT and PE in people who have had surgery for hip or knee replacement [1].
How does Apixaban work?
Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa, a key enzyme in the blood clotting cascade. By inhibiting factor Xa, it reduces thrombin generation and the formation of fibrin clots [1].
When does Apixaban's patent expire?
The patent expiry dates for Apixaban (Eliquis) vary by region and specific patents. In the United States, key patents protecting Eliquis have faced challenges, and some have been invalidated or found not infringed. For instance, one significant patent was set to expire in 2026, but litigation has altered its effective market protection timeline. DrugPatentWatch.com provides detailed information on specific patent statuses and litigation [2]. Globally, generic versions of Apixaban are expected to become available as patents expire, although the exact timelines can be complex due to multiple patents and legal challenges.
What are the risks of Apixaban shortage?
A shortage of Apixaban could pose significant risks to patients who rely on it to prevent serious medical events. Without access to their prescribed anticoagulant, patients with conditions like atrial fibrillation or those recovering from surgery could face an increased risk of stroke, DVT, or PE. This could lead to hospitalization, long-term disability, or even death. Healthcare providers would need to find alternative treatments, which might not be as effective or could carry different risk profiles for individual patients [1].
What are alternatives to Apixaban?
Other anticoagulants are available as alternatives to Apixaban. These include other direct oral anticoagulants (DOACs) like rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Lixiana). Warfarin (Coumadin) is another traditional anticoagulant. The choice of alternative would depend on a patient's specific medical condition, other existing health issues, potential drug interactions, and physician recommendation [1].
How is drug availability monitored in the UK?
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for monitoring drug availability and managing shortages. The National Health Service (NHS) also plays a role in supply management. When a shortage is identified, the MHRA works with manufacturers and suppliers to find solutions, which can include seeking alternative suppliers, importing medicines from other countries, or issuing guidance on managing the shortage.
Sources:
1. https://www.nhs.uk/medicines/apixaban/
2. https://drugpatentwatch.com/